BIOEQUIVALENCE OF TWO BRANDS OF CITALOPRAM 40 mg TABLETS AFTER SINGLE ORAL ADMINISTRATION TO HEALTHY VOLUNTEERS
propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile, is a drug which belongs to the group of specific serotonin reuptake inhibitors 1 . It is used alone or in combination with other antidepressive and antipsychotic drugs to help treat a variety of psychiatric disorders 2 . Citalopram has shown efficacy in placebo-controlled clinical studies 3, 4 and has been marketed in several countries for the treatment of major depression. Citalopram is a fine, white powder that is sparingly soluble in water and soluble in ethanol. It is available as film-coated, round or oval, white, scored tablets containing citalopram hydrobromide, corresponding to 10, 20, 30 or 40 mg of citalopram base and as infusion concentrate and drops containing citalopram hydrochloride.
The objective of this study was to evaluate, in healthy volunteers, the bioequivalence of a test formulation of the 40 mg (tablets) of citalopram elaborated by Abdi Ibrahim İlaç San. ve Tic A.Ş., Istanbul, Turkey (Citol) and a commercial formulation of 40 mg (tablets) of citalopram (Cipramil ® made by H. Lundbeck, Copenhagen, Denmark used as a reference formulation.
MATERIALS AND METHODS

Volunteers characteristics
Twenty-six healthy adult male volunteers aged between 18 and 50 years (29.0 ± 2.1 years, mean ± S.D.; range 27-32) and within the 15% of the ideal body weight, weight between 55.0 and 77.0 kg (65 ± 9.0), and height between 166 and 183 cm (177 ± 7.0), were selected for the study. The estimation of the number of subjects required was determined taking into account the error variance associated with the primary pharmacokinetic parameters as estimated from published data, the probability of the confidence interval for relative bioavailability (95 %), and the required power (80 %) 5 . All subjects gave written informed consent and the Local Ethics Committee (University Hospital in Olomouc) has approved the clinical protocol. All volunteers were assessed as healthy based on medical history, clinical examination, blood pressure, ECG and laboratory investigation (hematology, blood biochemistry and urine). There were no individuals with either a history or evidence of hepatic, renal, gastrointestinal, and hematological deviations, or any acute/chronic disease or drug allergy.
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The study was conducted in a randomized, single-dose, two-way, cross-over design with a 2-week washout period between two doses. During each period, the volunteers were admitted to hospital and after an overnight fasting they received a single reference or tested 40 mg citalopram tablet. Low-carbonate water (240 mL) was given immediately after drug administration. All volunteers fasted 2 h after the drug administration, thereafter they received unified snack. The standardized meals (lunch, afternoon snack, dinner and breakfast) were provided to volunteers 6, 9, 12 and 24 h after dosing. No other food was permitted during the first 24 h after drug administration. Liquid consumption was permitted ad libitum after lunch, however xanthine-containing drinks like tea, coffee and cola were avoided.
The study was performed in accordance with the guidelines of the revised Declaration of Helsinki on biomedical research involving subjects and the requirements of Good Clinical Practice.
Formulations and Sample Collection
The C until drug analysis. After a wash-out period of 14 days, the study was repeated in the same manner to complete the cross-over design.
Sample Preparation for HLPC Injection
Ten µl of the internal standard working solution (verapamil 100 µl/ml) was added to 1 ml plasma sample. The samples were vortexed for 2 min and 2 ml of a mixture of potassium dihydrogenphosphate and methanol (85:15, v/v) were added. This mixture was then shaken on a vortex mixer for 2 min and centrifuged at 2500 g for 5 min in order to spin down protein aggregates. The final supernatant was applied directly to a solid phase extraction column. Aliquots were loaded into an autosampler tray and volumes of 15 µl were injected into the column, where citalopram and the internal standard were separated from endogenous substances and their peak areas recorded.
HLPC analysis
All plasma samples were analysed for citalopram concentration according to a sensitive, selective, and accurate high-performance liquid chromatography (HLPC) method, which was developed and validated before the study at laboratories of I.Q.A.
The chromatographic separations and quantitative determination were performed using a high-performance liquid chromatograph from Agilent Technologies (HPST, Prague, Czech Republic): Model 1100 series, equipped with a degassing unit, quaternary pump, autoinjector, fluorescence detector, and controlled by Agilent Chem. Station software. Chromatographic separation was performed using Symmetry ® C 18 (dimethyl octadecylsilyl bonded amorphous silica; 150 × 3.9 mm id.; 5 µm particle size) HPLC column (Watters Corporation, Massachusetts, USA). The mobile phase consisted of acetonitrile (78 : 28) and ammonium formate (45 mmol/l, pH 4.0). The mobile phase was eluted at a flow rate of 0.8 ml/min at ambient room temperature. Fluorescence detection of citalopram and the internal standard was performed at an excitation wavelength of 249 nm and emission wavelength 302 mm. The peak area was measured, and the peak area ratio of the drug to the internal standard and the concentration were calculated. Each analysis required a maximum of 19 min. All samples from each single volunteer were measured on the same day in order to avoid inter-assay variation.
The calibration curves were linear over the range of 5-400 ng/ml using 1.0 ml plasma samples. The precision of the method, expressed as coefficients of variation (CV%), was 3.30, 9.50 and 3.15 %, respectively, for samples containing 20, 100 and 200 ng/ml, respectively. The accuracy value was within the allowed limits.
Pharmacokinetic and statistical analysis
Pharmacokinetic analysis was performed by means of a model-independent method using the GraphPad Prism (rev. 2.01), Lotus Approach and Lotus 1-2-3 (rev. 9) computer programs. The maximum citalopram plasma concentration (C max ) and the corresponding time of peak plasma concentration (T max ) were taken directly from the individual plasma data. The elimination rate constant (K el ) was estimated from the slope of the semilogarithmic plot of the terminal phase of the plasma concentrationtime curve calculated by linear regression and the elimination half-life (T 1/2 ) was generated by dividing ln 2 by the elimination rate constant K el. The area under the plasma concentration-time curve AUC 0-24 and the area to the infinity AUC 0-α were calculated by using the linear trapezoidal method. Extrapolation of these areas to infinity (AUC 0-α ) was done by adding the value C last /K el to the calculated AUC 0-24 (where C last = the last detectable concentration). The clearance (CL) was calculated using the following equation: (dose/body wt)/AUC 0-α.
For the purpose of bioequivalence analysis, two-way analysis of variance (ANOVA, GLM procedure) was used to assess the effect of formulations, periods, sequences, and subjects on AUC 0-24 , AUC 0-α and C max. The difference of two related parameters was considered statistically significant for p-values equal or less than 0.05.
RESULTS
Both citalopram formulations (Citol and Cipramil 40 mg tablets) were well tolerated by all the subjects; unexpected incidents that could have influenced the outcome of the study did not occur. There were no drop-outs Bioequivalence of two brands of Citalopram 40 mg tablets after single oral administration to healthy volunteers and the volunteers who had started the study continued to the end and were discharged from the hospital in good health condition. Both medications were readily absorbed from the gastrointestinal tract and citalopram was already measurable at the first sampling time (1 h) in all the volunteers. Plot of the citalopram mean plasma concentrations versus time for the two formulations over the 24-hr truncated sampling period is shown in Figure 1 . Descriptive statistics of the pharmacokinetic parameters AUC 0-24 , AUC 0-α , C max , T max , K el , T 1/2 , and CL for the test and reference formulations are summarized in Table 1 Table 2 shows the results of the bioequivalence analysis of the main pharmacokinetic parameters (AUC 0-24 , AUC 0-α and C max ). After log-transformation of the data, ANOVA for these parameters showed no significant difference between the two formulations (p > 0.05). Relative bioavailability was found to be 100.45 %, 100.08 % and 101.29 % of AUC 0-24 , AUC 0-α and C max , respectively, and the parametric 90 % confidence intervals for those pharmacokinetic parameter values lie entirely within the bioequivalence acceptance limits of 80 %-125 %.
DISCUSSION
The main objective of bioequivalence studies is to assure the safety and efficacy of generic formulations. Two formulations of the same drug are considered to be bioequivalent and per se therapeutically equivalent if they exhibit a comparable extent and rate of absorption, when they are administered in the same molar dose and under similar experimental conditions 6 . The 24-hr truncated sampling period used in this study, which is in agreement with EU guidance 7 for drugs with a long half-life (e.i. citalopram 36 hr), demonstrated that neither AUC nor C max were affected for such design. Those values were statistically analysed for determination of bioequivalence or biononequivalence. Other pharmacokinetic parameters (i.e. T max , CL, T 1/2 and K el ) results were used as supportive results in that truncated pharmacokinetic design.
This study was conducted on healthy volunteers according to the study protocol. All subjects received the same dosages of medication, i.e one single dose of 40 mg citalopram in the form of the test product or one single dose of 40 mg citalopram in the form of the reference product with a 14-day washout period. No adverse events necessitating subject withdrawal from the study were reported.
Statistical comparison of the main pharmacokinetic paramenters, AUC 0-24 , AUC 0-α and C max, clearly indicated no significant difference between Citol and Cipramil ® 40 mg tablets, in any of the calculated pharmacokinetic parameters. The obtained values were in good agreement with reported studies [8] [9] [10] . Since the 90 % CI for AUC 0-24 , AUC 0-α and C max mean ratios are within the 80 %-125 % interval, it was concluded that the tested formulation Citol (40 mg tablets) elaborated by Abdi Ibrahim İlaç San. ve Tic A.Ş., Istanbul, Turkey is bioequivalent to Cipramil ® 40 mg, for both extent and rate of absorption.
